User: Guest  Login
Document type:
journal article 
Author(s):
Muller, T; Glass, J; Muller, D; Link, A; Schenk, C; Rammes, G 
Title:
A new galenic formulation of selegiline (Xilopae) in the treatment of Parkinson disease 
Abstract:
Selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B). Selegiline is looked upon as a putative progression of Parkinson's disease (PD) delaying compound due to its in preclinical research proven neuroprotective modes of action. Xilopar(R) is a new formulation of selegiline, which facilitates absorption in the mouth and thus avoids hepatic first-pass metabolism. Intake of 1.25 mg Xilopar(R) provides similar pharmacokinetic plasma behaviour corresponding to oral admin...    »
 
Journal title abbreviation:
AKTUEL NEUROL 
Year:
2004 
Journal volume:
31 
Journal issue:
Pages contribution:
347-352 
Language:
eng 
Print-ISSN:
0302-4350 
TUM Institution:
sthesiologie